RT Journal Article
T1 Penicillin and cephalosporin cross-reactivity: role of side chain and synthetic cefadroxil epitopes.
A1 Bogas, Gador
A1 Mayorga, Cristobalina
A1 Martín-Serrano, Ángela
A1 Fernández-Santamaría, Rubén
A1 Jiménez-Sánchez, Isabel M
A1 Ariza, Adriana
A1 Barrionuevo, Esther
A1 Posadas, Teresa
A1 Salas, María
A1 Fernández, Tahía Diana
A1 Torres, María José
A1 Montañez, María Isabel
K1 Amoxicillin
K1 Antigenic determinant
K1 Betalactam
K1 Cephalosporin
K1 Cross-reactivity
K1 Drug allergy
K1 Specific IgE
AB Analysis of cross-reactivity is necessary for prescribing safe cephalosporins for penicillin allergic patients. Amoxicillin (AX) is the betalactam most often involved in immediate hypersensitivity reactions (IHRs), and cefadroxil (CX) the most likely cephalosporin to cross-react with AX, since they share the same R1 side chain, unlike cefuroxime (CO), with a structurally different R1. We aimed to analyse cross-reactivity with CX and CO in patients with confirmed IHRs to AX, including sIgE recognition to AX, CX, CO, and novel synthetic determinants of CX. Fifty-four patients with confirmed IHRs to AX based on skin test (ST) and/or drug provocation test (DPT) were included. Serum sIgE to AX and benzylpenicillin was determined by Radioallergosorbent test (RAST). Two potential determinants of CX, involving intact or modified R1 structure, with open betalactam ring, were synthesised and sIgE evaluated by RAST inhibition assay. Tolerance to CX (Group A) was observed in 64.8% cases and cross-reactivity in 35.2% cases (Group B). Cross-reactivity with CO was only found in 1.8% cases from Group B. ST to CX showed a negative predictive value of 94.6%. RAST inhibition assays showed higher recognition to CX as well as to both synthetic determinants (66% of positive cases) in Group B. Cross-reactivity with CX in AX allergic patients is 35%, being ST not enough for prediction. R1, although critical for recognition, is not the unique factor. The synthetic determinants of CX, 1-(HOPhG-Ser-Bu) and 2-(pyrazinone) are promising tools for determining in vitro cross-reactivity to CX in AX allergic patients.
SN 2045-7022
YR 2020
FD 2020-12-04
LK https://hdl.handle.net/10668/24975
UL https://hdl.handle.net/10668/24975
LA en
DS RISalud
RD Apr 5, 2025